Further studies on the functional activity of the new analogs—including their affinity for the VDR using a fluorescence-based assay, calcium activity in vitro and in vivo, as well as anticancer activity in leukemia and ovarian cancer cell lines in vitro, and prostate cancer models both in vitro and in vivo—are currently underway in collaborating laboratories. This evidence concerns the gene VDR and ovarian cancer.